Cited by 1,308Cancer-related Molecular PathwaysChromatin Remodeling and CancerPI3K/AKT/mTOR signaling in cancer

The DOI matches its Crossref record; 57 of the 64 references it cites were found in a registry or an index.

Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome

Open access

Olive, Kenneth P., Tuveson, David A., Ruhe, Zachary C., Yin, Bob, Willis, Nicholas A., Bronson, Roderick T., Crowley, Denise, Jacks, Tyler·2004·Cell

DOI 10.1016/j.cell.2004.11.004

Open this paper in CoChat — free account Open PDF

Abstract

The p53 tumor suppressor gene is commonly altered in human tumors, predominantly through missense mutations that result in accumulation of mutant p53 protein. These mutations may confer dominant-negative or gain-of-function properties to p53. To ascertain the physiological effects of p53 point mutation, the structural mutant p53R172H and the contact mutant p53R270H (codons 175 and 273 in humans) were engineered into the endogenous p53 locus in mice. p53R270H/+ and p53R172H/+ mice are models of Li-Fraumeni Syndrome; they developed allele-specific tumor spectra distinct from p53+/- mice. In addition, p53R270H/- and p53R172H/- mice developed novel tumors compared to p53-/- mice, including a variety of carcinomas and more frequent endothelial tumors. Dominant effects that varied by allele and function were observed in primary cells derived from p53R270H/+ and p53R172H/+ mice. These results demonstrate that point mutant p53 alleles expressed under physiological control have enhanced oncogenic potential beyond the simple loss of p53 function.

Integrity signals

Registry

Crossref · 10.1016/j.cell.2004.11.004

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
QUANTITATIVE STUDIES OF THE GROWTH OF MOUSE EMBRYO CELLS IN CULTURE AND THEIR DEVELOPMENT INTO ESTABLISHED LINES
Todaro, G. J., & Green, H. (1963) · The Journal of Cell Biology · doi:10.1083/jcb.17.2.299 · Cited by 2,747
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,559
T antigen is bound to a host protein in SY40-transformed cells
Lane, D. P., & Crawford, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,456
p63, a p53 Homolog at 3q27–29, Encodes Multiple Products with Transactivating, Death-Inducing, and Dominant-Negative Activities
Yang, A., Kaghad, M., Wang, Y., Gillett, E. S., Fleming, M. D., Dötsch, V., Andrews, N. C., Caput, D., & McKeon, F. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80275-0 · Cited by 2,118
Tumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
The p53 proto-oncogene can act as a suppressor of transformation
Finlay, C. A., Hinds, P. W., & Levine, A. J. (1989) · Cell · doi:10.1016/0092-8674(89)90045-7 · Cited by 1,987

Flagged first, then by citations

Show all 64 references

7 of the 64 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

Hinds, 1990, Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells, Cell Growth Differ, 1, 571
Kleihues, 1997, Tumors associated with p53 germline mutations, Am. J. Pathol, 150, 1

Sorted by citations

Items 401–500 of 1,000

Emerging Non-Canonical Functions and Regulation by p53: p53 and Stemness
Olivos, D. J., & Mayo, L. D. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17121982 · Cited by 67
CAR T Cell Locomotion in Solid Tumor Microenvironment
Nguyen, D., Ogando‐Rivas, E., Liu, R., Wang, T., Rubin, J. A., Jin, L., Tao, H., Sawyer, W. W., Méndez‐Gómez, H. R., Cascio, M., et al. (2022) · Cells · doi:10.3390/cells11121974 · Cited by 65
Cognate DNA Stabilizes the Tumor Suppressor p53 and Prevents Misfolding and Aggregation
Ishimaru, D., Bom, A. P. D. A., Lima, L. M. T. R., Quesado, P. A., Oyama, M. F. C., Gallo, C. V. D. M., Cordeiro, Y., & Silva, J. L. (2009) · Biochemistry · doi:10.1021/bi9003028 · Cited by 64
Suppression of Inhibitor of Differentiation 2, a Target of Mutant p53, Is Required for Gain-of-Function Mutations
Yan, W., Liu, G., Scoumanne, A., & Chen, X. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0810 · Cited by 65
Small molecule compounds targeting the p53 pathway: are we finally making progress?
Yu, X., Narayanan, S., Vázquez, A., & Carpizo, D. R. (2014) · APOPTOSIS · doi:10.1007/s10495-014-0990-3 · Cited by 68
Mice Expressing a Mammary Gland–Specific R270H Mutation in the p53 Tumor Suppressor Gene Mimic Human Breast Cancer Development
Wijnhoven, S., Zwart, E., Speksnijder, E. N., Beems, R. B., Olive, K. P., Tuveson, D. A., Jonkers, J., Schaap, M. M., van den Berg, J., Jacks, T., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1650 · Cited by 64
TP53 mutation, mitochondria and cancer
Kamp, W. M., Wang, P., & Hwang, P. M. (2016) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2016.02.007 · Cited by 63
miRNA-126 Orchestrates an Oncogenic Program in B Cell Precursor Acute Lymphoblastic Leukemia
Nucera, S., Giustacchini, A., Boccalatte, F. E., Calabria, A., Fanciullo, C., Plati, T., Ranghetti, A., García-Manteiga, J. M., Cittaro, D., Benedicenti, F., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.007 · Cited by 65
The MDM2–p53–pyruvate carboxylase signalling axis couples mitochondrial metabolism to glucose-stimulated insulin secretion in pancreatic β-cells
Li, X., Cheng, K. K. Y., Liu, Z., Yang, J., Wang, B., Jiang, X. X., Zhou, Y., Hallenborg, P., Hoo, R. L. C., Lam, K. S. L., et al. (2016) · Nature Communications · doi:10.1038/ncomms11740 · Cited by 64
p53 Downregulates Its Activating Vaccinia-Related Kinase 1, Forming a New Autoregulatory Loop
Valbuena, A., Vega, F. M. D. L., Blanco, S., & Lazo, P. A. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00069-06 · Cited by 63
p53‐mediated adaptation to serine starvation is retained by a common tumour‐derived mutant
Humpton, T. J., Hock, A. K., Maddocks, O. D. K., & Vousden, K. H. (2018) · Cancer & Metabolism · doi:10.1186/s40170-018-0191-6 · Cited by 58
A Meta-Analysis of the Relationship between FGFR3 and TP53 Mutations in Bladder Cancer
Neuzillet, Y., Paolettí, X., Ouerhani, S., Mongiat-Artus, P., Soliman, H. R., de Thé, H., Sibony, M., Denoux, Y., Molinié, V., Hérault, A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048993 · Cited by 66
Drastic Effect of GermlineTP53Missense Mutations in Li-Fraumeni Patients
Zerdoumi, Y., Aury‐Landas, J., Bonaïti‐Pellié, C., Derambure, C., Sesboüé, R., Renaux‐Petel, M., Frébourg, T., Bougeard, G., & Flaman, J. (2012) · Human Mutation · doi:10.1002/humu.22254 · Cited by 63
Urodele p53 tolerates amino acid changes found in p53 variants linked to human cancer
Villiard, É., Brinkmann, H., Moiseeva, O. V., Mallette, F. A., Ferbeyre, G., & Roy, S. (2007) · BMC Evolutionary Biology · doi:10.1186/1471-2148-7-180 · Cited by 61
Antiproliferative Effect of Androgen Receptor Inhibition in Mesenchymal Stem-Like Triple-Negative Breast Cancer
Zhu, A., Li, Y., Song, W., Xu, Y., Yang, F., Zhang, W., Yin, Y., & Guan, X. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000443052 · Cited by 63
Crippling p53 activities via knock-in mutations in mouse models
Iwakuma, T., & Lozano, G. (2007) · Oncogene · doi:10.1038/sj.onc.1210278 · Cited by 66
Induction of genetic instability by gain-of-function p53 cancer mutants
Xu, Y. (2008) · Oncogene · doi:10.1038/sj.onc.1211023 · Cited by 63
Mutant p53 gain of function is interwoven into the hallmarks of cancer
Solomon, H., Madar, S., & Rotter, V. (2011) · The Journal of Pathology · doi:10.1002/path.2988 · Cited by 62
Gain of Oncogenic Function of p53 Mutants Induces Invasive Phenotypes in Human Breast Cancer Cells by Silencing CCN5/WISP-2
Dhar, G., Banerjee, S., Dhar, K., Tawfik, O. W., Mayo, M. S., VanVeldhuizen, P. J., & Banerjee, S. K. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0316 · Cited by 62
Integrative genome analysis of somatic p53 mutant osteosarcomas identifies Ets2-dependent regulation of small nucleolar RNAs by mutant p53 proteinPreprint
Pourebrahim, R., Zhang, Y., Liu, B., Gao, R., Xiong, S., Lin, P. P., McArthur, M. J., Ostrowski, M. C., & Lozano, G. (2017) · Genes & Development · doi:10.1101/gad.304972.117 · Cited by 62
Hotspot mutant p53-R273H inhibits KLF6 expression to promote cell migration and tumor metastasis
Sun, S., Chen, H., Sun, L., Wang, M., Wu, X., & Xiao, Z. J. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02814-1 · Cited by 61
A Balancing Act: p53 Activity from Tumor Suppression to Pathology and Therapeutic Implications
Wang, M., & Attardi, L. D. (2021) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-042320-025840 · Cited by 61
Specific regulation of BACH1 by the hotspot mutant p53R175H reveals a distinct gain-of-function mechanism
Su, Z., Kon, N., Yi, J., Zhao, H., Zhang, W., Tang, Q., Li, H., Kobayashi, H. H., Li, Z., Duan, S., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00532-z · Cited by 64
Targeting mutant p53: a key player in breast cancer pathogenesis and beyond
Qayoom, H., Haq, B. U., Sofi, S., Jan, N., Jan, A., & Mir, M. A. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01863-9 · Cited by 68
Differences between KC and KPC pancreatic ductal adenocarcinoma mice models, in terms of their modeling biology and their clinical relevance
Gabriel, A. N. A., Jiao, Q., Umwali, Y., Yang, X., Al-Ameri, S. A. A.-E., Du, L., Wang, Y., & Wang, C. (2019) · Pancreatology · doi:10.1016/j.pan.2019.11.006 · Cited by 64
Metabolic regulation by p53 prevents R-loop-associated genomic instability
Panatta, E., Butera, A., Mammarella, E., Pitolli, C., Mauriello, A., Leist, M., Knight, R. A., Melino, G., & Amelio, I. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111568 · Cited by 60
Mutant p53 Drives Cancer Metastasis via RCP-Mediated Hsp90α Secretion
Zhang, S., Wang, C., Ma, B., Xu, M., Xu, S., Liu, J., Tian, Y., Fu, Y., & Luo, Y. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107879 · Cited by 61
The p53 Pathway and Outcome among Patients with T1G3 Bladder Tumors
López‐Knowles, E., Hernandez, S. F., Kogevinas, M., Lloreta, J., Amorós, À., Tardón, A., Carrato, A., Kishore, S. A., Serra, C., Malats, N., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0206 · Cited by 60
Illuminating p53 function in cancer with genetically engineered mouse models
Garcia, P. B., & Attardi, L. D. (2014) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2013.12.014 · Cited by 65
Mutant p53R270H gain of function phenotype in a mouse model for oncogene‐induced mammary carcinogenesis
Heinlein, C., Krepulat, F., Löhler, J., Speidel, D., Deppert, W., & Tolstonog, G. V. (2007) · International Journal of Cancer · doi:10.1002/ijc.23317 · Cited by 59
Rap2b, a novel p53 target, regulates p53-mediated pro-survival function
Zhang, X., He, Y., Lee, K. H., Dubois, W., Li, Z., Wu, X., Kovalchuk, A. L., Zhang, W., & Huang, J. L. (2013) · Cell Cycle · doi:10.4161/cc.24364 · Cited by 59
Loss of p53 and Ink4a/Arf Cooperate in a Cell Autonomous Fashion to Induce Metastasis of Hepatocellular Carcinoma Cells
Chen, Y., Klimstra, D. S., Mongeau, M. E., Tatem, J. L., Boyartchuk, V., & Lewis, B. C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0381 · Cited by 59
Promyelocytic Leukemia Protein is Required for Gain of Function by Mutant p53
Haupt, S., Agostino, S. D., Mizrahi, I., Alsheich-Bartok, O., Voorhoeve, M., Damalas, A., Blandino, G., & Haupt, Y. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4010 · Cited by 62
Mouse Models for the p53 R72P Polymorphism Mimic Human Phenotypes
Zhu, F., Dollé, M. E. T., Berton, T. R., Kuiper, R., Capps, C., Espejo, A. B., McArthur, M. J., Bedford, M. T., STEEG, H. V., de Vries, A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4646 · Cited by 62
Cross-Talk between p53 and Wnt Signaling in Cancer
Xiao, Q., Werner, J., Venkatachalam, N., Boonekamp, K. E., Ebert, M. P. A., & Zhan, T. (2022) · Biomolecules · doi:10.3390/biom12030453 · Cited by 59
The mutant p53 mouse as a pre-clinical model
Jackson, J. G., & Lozano, G. (2013) · Oncogene · doi:10.1038/onc.2012.610 · Cited by 57
Cancer early dissemination: cancerous epithelial-mesenchymal transdifferentiation and transforming growth factor signalling
Sabe, H. (2011) · The Journal of Biochemistry · doi:10.1093/jb/mvr044 · Cited by 59
Redox modulation of adipocyte differentiation: hypothesis of “Redox Chain” and novel insights into intervention of adipogenesis and obesity
Wang, X., & Hai, C. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.07.012 · Cited by 59
A porcine model of osteosarcoma
Saalfrank, A., Janssen, K., Ravon, M., Flisikowski, K., Eser, S., Steiger, K., Flisikowska, T., Müller-Fliedner, P., Schulze, É. A., Brönner, C., et al. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.19 · Cited by 58
Nrf2 promotes mutant K-ras/p53-driven pancreatic carcinogenesis
Hamada, S., Taguchi, K., Masamune, A., Yamamoto, M. P., & Shimosegawa, T. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx043 · Cited by 58
Impact of Carcinogenic Chromium on the Cellular Response to Proteotoxic Stress
Ferreira, L. M. R., Cunha‐Oliveira, T., Sobral, M. C. M., Abreu, P. L., Alpoim, M. C., & Urbano, A. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194901 · Cited by 62
Mouse Models of Human Non-Small-Cell Lung Cancer: Raising the BarPreprint
KIM, C. F. B., Jackson, E. L., Kirsch, D. G., Grimm, J., Shaw, A. T., Lane, K. M., Kissil, J. L., Olive, K. P., Sweet-Cordero, A., Weissleder, R., et al. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.037 · Cited by 58
Metal ion interference therapy: metal-based nanomaterial-mediated mechanisms and strategies to boost intracellular “ion overload” for cancer treatment
Li, Y., Wang, Y., Li, Z., Stenzel, M. H., & Jiang, Y. (2024) · Materials Horizons · doi:10.1039/d4mh00470a · Cited by 60
Targeting the Ubiquitin-Mediated Proteasome Degradation of p53 for Cancer Therapy
DeVine, T., & Dai, M. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319180009 · Cited by 58
Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival
Mullany, L. K., Wong, K., Marciano, D. C., Katsonis, P., King, E. R., Ren, Y. A., Lichtarge, O., & Richards, J. S. (2015) · Neoplasia · doi:10.1016/j.neo.2015.10.003 · Cited by 59
Ninjurin 1 has two opposing functions in tumorigenesis in a p53-dependent manner
Yang, H. J., Zhang, J., Yan, W., Cho, S.-J., Lucchesi, C. A., Chen, M., Huang, E. C., Scoumanne, A., Zhang, W., & Chen, X. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1711814114 · Cited by 62
The BRG1/SOX9 axis is critical for acinar cell–derived pancreatic tumorigenesis
Tsuda, M., Fukuda, A., Roy, N., Hiramatsu, Y., Leonhardt, L., Kakiuchi, N., Hoyer, K., Ogawa, S., Goto, N., Ikuta, K., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci94287 · Cited by 62
Mutant p53 oncogenicity: dominant-negative or gain-of-function?
Stein, Y., Aloni-Grinstein, R., & Rotter, V. (2020) · Carcinogenesis · doi:10.1093/carcin/bgaa117 · Cited by 62
History and emerging trends in chemotherapy for gastric cancer
Yamashita, K., Hosoda, K., Niihara, M., & Hiki, N. (2021) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12439 · Cited by 60
Structural and Functional Basis for Therapeutic Modulation of p53 Signaling
Bassett, E. A., Wang, W., Rastinejad, F., & El‐Deiry, W. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1526 · Cited by 57
Identification of Small Molecules that Modulate Mutant p53 Condensation
Lemos, C., Schulze, L., Weiske, J., Meyer, H., Braeuer, N., Barak, N. N., Eberspächer, U., Werbeck, N. D., Stresemann, C., Lange, M., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101517 · Cited by 56
Mutant p53 gains oncogenic functions through a chromosomal instability-induced cytosolic DNA response
Zhao, M., Wang, T., Gleber‐Netto, F. O., Chen, Z., McGrail, D. J., Gomez, J. A., Ju, W., Gadhikar, M. A., Ma, W., Shen, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44239-2 · Cited by 63
Type I to Type II Ovarian Carcinoma Progression
WU, R. T., Baker, S. J., Hu, T. C., Norman, K. M., Fearon, E. R., & Cho, K. R. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.12.031 · Cited by 56
Gain of function of mutant p53: R282W on the peak?
Zhang, Y., Coillie, S. V., Fang, J.-Y., & Xu, J. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.8 · Cited by 59
Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers
Ferraiuolo, M. A., Verduci, L., Blandino, G., & Strano, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18050961 · Cited by 56
Development of multi-drug loaded PEGylated nanodiamonds to inhibit tumor growth and metastasis in genetically engineered mouse models of pancreatic cancer
Madamsetty, V. S., Pal, K., Keshavan, S., Caulfield, T. R., Dutta, S. K., Wang, E., Fadeel, B., & Mukhopadhyay, D. (2019) · Nanoscale · doi:10.1039/c9nr05478b · Cited by 56
Loss of wild-type p53 promotes mutant p53-driven metastasis through acquisition of survival and tumor-initiating properties
Nakayama, M., Hong, C. P., Oshima, H., Sakai, E., Kim, S., & Oshima, M. (2020) · Nature Communications · doi:10.1038/s41467-020-16245-1 · Cited by 55
Pathways involved in sunburn cell formation: deregulation in skin cancer
Claerhout, S., Laethem, A. V., Agostinis, P., & Garmyn, M. (2005) · Photochemical & Photobiological Sciences · doi:10.1039/b504970a · Cited by 56
The Activating Transcription Factor 3 Protein Suppresses the Oncogenic Function of Mutant p53 Proteins
Wei, S., Wang, H., Lu, C., Malmut, S., Zhang, J., Ren, S., Yu, G., Wang, W., Tang, D. D., & Yan, C. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.503755 · Cited by 56
Prognostic and histogenetic roles of gene alteration and the expression of key potentially actionable targets in salivary duct carcinomas
Shimura, T., Tada, Y., Hirai, H., Kawakita, D., Kano, S., Tsukahara, K., Shimizu, A., Takase, S., Imanishi, Y., Ozawa, H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22927 · Cited by 55
Oncogenic transformation and experimental models of human cancer
Anna, C. S. (2007) · Frontiers in bioscience · doi:10.2741/2661 · Cited by 56
Mutant p53 in cell-cell interactionsPreprint
Pilley, S. E., Rodríguez, T. A., & Vousden, K. H. (2021) · Genes & Development · doi:10.1101/gad.347542.120 · Cited by 54
The p53 tumor suppressor network in cancer and the therapeutic modulation of cell death
Chari, N. S., Pinaire, N. L., Thorpe, L., Medeiros, L. J., Routbort, M. J., & McDonnell, T. J. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0327-9 · Cited by 54
Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via Notch suppression
Court, H., Amoyel, M., Hackman, M., Lee, K. E., Xu, R., Miller, G., Bar‐Sagi, D., Bach, E. A., BergÃ¶, M. O., & Philips, M. R. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65764 · Cited by 54
Transcriptional functionality of germ line p53 mutants influences cancer phenotype
Monti, P., Ciribilli, Y., Jordan, J., Menichini, P., Umbach, D. M., Resnick, M. A., Luzzatto, L., Inga, A., & Fronza, G. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2545 · Cited by 58
p53 in head and neck cancer: Functional consequences and environmental implications of TP53mutations
Peltonen, J. K., Helppi, H. M., Pääkkö, P. K., Turpeenniemi-Hujanen, T. M., & Vähäkangas, K. (2010) · Head & Neck Oncology · doi:10.1186/1758-3284-2-36 · Cited by 55
Li–Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53
Zhou, R., Xu, A., Gingold, J. A., Strong, L. C., Zhao, R., & Lee, D. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.07.004 · Cited by 52
Notch Signaling in Skeletal Stem Cells
Chen, S., Lee, B., & Bae, Y. (2013) · Calcified Tissue International · doi:10.1007/s00223-013-9773-z · Cited by 53
Rescue of embryonic stem cells from cellular transformation by proteomic stabilization of mutant p53 and conversion into WT conformation
Rivlin, N., Katz, S., Doody, M., Sheffer, M., Horesh, S., Molchadsky, A., Koifman, G., Shetzer, Y., Goldfinger, N., Rotter, V., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320428111 · Cited by 52
Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes
Redman, L. N., Shaver, T. M., Jin, H., Marshall, C. B., Schafer, J. M., Sheng, Q., Hongo, R. A., Beckermann, K. E., Wheeler, F. C., Lehmann, B. D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25359-z · Cited by 55
Underlying mechanisms and drug intervention strategies for the tumour microenvironment
Li, H., Zhou, L., Zhou, J., Li, Q., & Ji, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01893-y · Cited by 51
TP53 mutations in head and neck cancer
Nathan, C. O., Khandelwal, A. R., Wolf, G. T., Rodrigo, J. P., Mäkitie, A. A., Saba, N. F., Forastiere, A. A., Bradford, C. R., & Ferlito, A. (2022) · Molecular Carcinogenesis · doi:10.1002/mc.23385 · Cited by 55
Mutant p53 expression in fallopian tube epithelium drives cell migration
Quartuccio, S. M., Karthikeyan, S., Eddie, S. L., Lantvit, D. D., hAinmhire, E. Ó., Modi, D., Wei, J., & Burdette, J. E. (2015) · International Journal of Cancer · doi:10.1002/ijc.29528 · Cited by 51
Arsenic Trioxide Reactivates Proteasome-Dependent Degradation of Mutant p53 Protein in Cancer Cells in Part via Enhanced Expression of Pirh2 E3 Ligase
Yan, W., Jung, Y.-S., Zhang, Y., & Chen, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103497 · Cited by 53
Single nucleotide variation in the TP53 3′ untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program
Li, Y., Gordon, M. W., Xu-Monette, Z. Y., Visco, C., Tzankov, A., Zou, D., Qiu, L., Montes‐Moreno, S., Dybkær, K., Orazi, A., et al. (2013) · Blood · doi:10.1182/blood-2012-12-471722 · Cited by 53
TP53mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer
CHIEN, J. R., Sicotte, H., Fan, J., Humphray, S., Cunningham, J. M., Kalli, K. R., Oberg, A. L., Hart, S. N., Li, Y., Davila, J. I., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv111 · Cited by 51
Cancer mouse models: Past, present and future
Khaled, W. T., & Liu, P. (2014) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2014.04.003 · Cited by 52
Pleiotropic Role of HSF1 in Neoplastic Transformation
Vydra, N., Toma-Jonik, A., & Widłak, W. (2014) · Current Cancer Drug Targets · doi:10.2174/1568009614666140122155942 · Cited by 51
Understanding the Osteosarcoma Pathobiology: A Comparative Oncology Approach
Varshney, J., Scott, M. C., Largaespada, D. A., & Subramanian, S. (2016) · Veterinary Sciences · doi:10.3390/vetsci3010003 · Cited by 51
p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer
Powell, E., Shao, J., Yuan, Y., Chen, H.-C., Cai, S., Echeverria, G. V., Mistry, N. A., Decker, K. F., Schlosberg, C., Do, K.-A., et al. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0673-9 · Cited by 50
Ovarian tumour growth is characterized by mevalonate pathway gene signature in an orthotopic, syngeneic model of epithelial ovarian cancer
Greenaway, J. B., Virtanen, C., Osz, K., Révay, T., Hardy, D. B., Shepherd, T. G., DiMattia, G. E., & Petrik, J. (2016) · Oncotarget · doi:10.18632/oncotarget.10121 · Cited by 51
Loss of Function of Canonical Notch Signaling Drives Head and Neck Carcinogenesis
Nyman, P. E., Buehler, D. G., & Lambert, P. F. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3535 · Cited by 51
PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma
Ganci, F., Pulito, C., Valsoni, S., Sacconi, A., Turco, C., Vahabi, M., Manciocco, V., Mazza, E. M. C., Meens, J., Karamboulas, C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2485 · Cited by 51
Mouse Models of Lung Cancer
Dutt, A., & Wong, K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0414 · Cited by 53
Identification of FoxR2 as an Oncogene in Medulloblastoma
Koso, H., Tsuhako, A., Lyons, E., Ward, J. M., Rust, A. G., Adams, D. J., Jenkins, N. A., Copeland, N. G., & Watanabe, S. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1523 · Cited by 52
Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells
Hosain, S. B., Khiste, S., Uddin, M. B., Vorubindi, V., Ingram, C., Zhang, S., Hill, R. A., Gu, X., & Liu, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.11169 · Cited by 53
Sleeping Beauty Insertional Mutagenesis Reveals Important Genetic Drivers of Central Nervous System Embryonal Tumors
Beckmann, P. J., Larson, J. D., Larsson, A. T., Ostergaard, J., Wagner, S., Rahrmann, E. P., Shamsan, G. A., Otto, G. M., Williams, R. L., Wang, J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1261 · Cited by 47
Autophagy induced by SAHA affects mutant P53 degradation and cancer cell survival
Foggetti, G., Ottaggio, L., Russo, D., Mazzitelli, C., Monti, P., Degan, P., Miele, M., Fronza, G., & Menichini, P. (2019) · Bioscience Reports · doi:10.1042/bsr20181345 · Cited by 51
Mutant p53 proteins: Between loss and gain of function
Strano, S., Dell’Orso, S., Mongiovi, A. M., Monti, O., Lapi, E., Agostino, S. D., Fontemaggi, G., & Blandino, G. (2006) · Head & Neck · doi:10.1002/hed.20531 · Cited by 50
Progress and applications of mouse models for human lung cancer
Seranno, S. D., & Meuwissen, R. L. J. (2010) · European Respiratory Journal · doi:10.1183/09031936.00124709 · Cited by 50
Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell FormationPreprint
Shetzer, Y., Molchadsky, A., & Rotter, V. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026203 · Cited by 53
Loss of protein phosphatase 2A regulatory subunit B56δ promotes spontaneous tumorigenesis in vivo
Lambrecht, C., Libbrecht, L., Sagaert, X., Pauwels, P., Hoorne, Y., Crowther, J., Louis, J. V., Sents, W., Sablina, A., & Janssens, V (2018) · Oncogene · doi:10.1038/onc.2017.350 · Cited by 50
Gain‐of‐function mutant p53 but not p53 deletion promotes head and neck cancer progression in response to oncogenic K‐ras
Acı́n, S., Li, Z., Mejia, O., Roop, D. R., El‐Naggar, A. K., & Caulı́n, C. (2011) · The Journal of Pathology · doi:10.1002/path.2971 · Cited by 49
Combined PTEN Mutation and Protein Expression Associate with Overall and Disease-Free Survival of Glioblastoma Patients
Xu, J., Li, Z., Wang, J., Chen, H., & Fang, J. (2014) · Translational Oncology · doi:10.1016/j.tranon.2014.02.004 · Cited by 49
Germline TP53 mutations result into a constitutive defect of p53 DNA binding and transcriptional response to DNA damage
Zerdoumi, Y., Lanos, R., Raad, S., Flaman, J., Bougeard, G., Frébourg, T., & Tournier, I. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx106 · Cited by 52
Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response
Zhang, P., Kitchen-Smith, I., Xiong, L., Stracquadanio, G., Brown, K. A., Richter, P., Wallace, M. D., Bond, E. E., Sahgal, N., Moore, S., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-0177 · Cited by 46
TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation
George, B., Kantarjian, H. M., Baran, N., Krocker, J. D., & Rios, A. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910782 · Cited by 53
p53: a two-faced cancer gene
Kastan, M. B., & Berkovich, E. (2007) · Nature Cell Biology · doi:10.1038/ncb0507-489 · Cited by 49
Evasion of Cell Senescence Leads to Medulloblastoma Progression
Tamayo-Orrego, L., Wu, C., Bouchard, N., Khedher, A., Swikert, S. M., Remke, M., Skowron, P., Taylor, M. D., & Charron, F. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.02.061 · Cited by 52
p53-Autophagy-Metastasis Link
Denisenko, T. V., Pivnyuk, A. D., & Zhivotovsky, B. (2018) · Cancers · doi:10.3390/cancers10050148 · Cited by 51

Authors: Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T.
Affiliations: Massachusetts Institute of Technology (US)
Abramson Cancer Center (US)
Tufts University (US)
Howard Hughes Medical Institute (US)
Corresponding author: Jacks, Tyler
ORCID: Olive, Kenneth P.
Tuveson, David A.
Ruhe, Zachary C.
Willis, Nicholas A.
Bronson, Roderick T.
Jacks, Tyler
Venue: Cell
Publisher: Elsevier BV
Published: 2004-12
Volume: 119
Issue: 6
Pages: 847-860
ISSN: 0092-8674 (ISSN-L)
DOI: 10.1016/j.cell.2004.11.004
OpenAlex: W2079852484
Cited by: 1,308
References: 64
Citations by year: 2026: 26 · 2025: 49 · 2024: 52 · 2023: 87 · 2022: 52 · 2021: 64 · 2020: 67 · 2019: 69 · 2018: 74 · 2017: 69 · 2016: 78 · 2015: 75 · 2014: 97 · 2013: 64 · 2012: 51
FWCI: 21.50
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 3150 d)
Locations: Cell (publishedVersion)
PubMed (publishedVersion)
The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords: p53, Li-Fraumeni syndrome, gain-of-function mutations, missense mutations, dominant-negative p53, tumor suppressor, mouse model, endothelial tumors, carcinoma, oncogenicity
MeSH terms: Alleles, Animals, Carcinoma, Mice, Transgenic, Mutation, Neoplasms, T-Lymphocytes, Gene Expression Regulation, Neoplastic, Genes, p53, Li-Fraumeni Syndrome, Apoptosis, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks